Loading...
Search for:
pancreas-cancer
0.009 seconds
Whole-genome analysis of de novo somatic point mutations reveals novel mutational biomarkers in pancreatic cancer
, Article Cancers ; Volume 13, Issue 17 , 2021 ; 20726694 (ISSN) ; Mohseni, A ; Dashti, H ; Beheshti, A ; Dehzangi, A ; Rabiee, H. R ; Alinejad Rokny, H ; Sharif University of Technology
MDPI
2021
Abstract
It is now known that at least 10% of samples with pancreatic cancers (PC) contain a causative mutation in the known susceptibility genes, suggesting the importance of identifying cancer-associated genes that carry the causative mutations in high-risk individuals for early detection of PC. In this study, we develop a statistical pipeline using a new concept, called gene-motif, that utilizes both mutated genes and mutational processes to identify 4211 3-nucleotide PC-associated gene-motifs within 203 significantly mutated genes in PC. Using these gene-motifs as distinguishable features for pancreatic cancer subtyping results in identifying five PC subtypes with distinguishable phenotypes and...
The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017
, Article The Lancet Gastroenterology and Hepatology ; Volume 4, Issue 12 , 2019 , Pages 934-947 ; 24681253 (ISSN) ; Sepanlou, S. G ; Ikuta, K. S ; Bisignano, C ; Safiri, S ; Roshandel, G ; Sharif, M ; Khatibian, M ; Fitzmaurice, C ; Nixon, M. R ; Abbasi, N ; Afarideh, M ; Ahmadian, E ; Akinyemiju, T ; Alahdab, F ; Alam, T ; Alipour, V ; Allen, C. A ; Anber, N. H ; Ansari Moghaddam, A ; Arabloo, J ; Badawi, A ; Bagherzadeh, M ; Belayneh, Y. M ; Biadgo, B ; Bijani, A ; Biondi, A ; Bjørge, T ; Borzì, A. M ; Bosetti, C ; Briko, A. N ; Briko, N. I ; Carreras, G ; Carvalho, F ; Choi, J. Y .J ; Chu, D. T ; Dang, A. K ; Daryani, A ; Davitoiu, D.V ; Demoz, G. T ; Desai, R ; Dey, S ; Do, H. T ; Do, H. P ; Eftekhari, A ; Esteghamati, A ; Farzadfar, F ; Fernandes, E ; Filip, I ; Fischer, F ; Foroutan, M ; Gad, M. M ; Gallus, S ; Geta, B ; Gorini, G ; Hafezi Nejad, N ; Harvey, J. D ; Hasankhani, M ; Hasanzadeh, A ; Hassanipour, S ; Hay, S. I ; Hidru, H. D ; Hoang, C. L ; Hostiuc, S ; Househ, M ; Ilesanmi, O. S ; Ilic, M. D ; Irvani, S. S. N ; Balalami, N. J ; James, S. L ; Joukar, F ; Kasaeian, A ; Kassa, T. D ; Kengne, A. P ; Khalilov, R ; Khan, E. A ; Khater, A ; Shadmani, F. K ; Kocarnik, J. M ; Komaki, H ; Koyanagi, A ; Kumar, V ; La Vecchia, C ; Lopukhov, P. D ; Manafi, F ; Manafi, N ; Manda, A. L ; Mansour Ghanaei, F ; Mehta, D ; Mehta, V ; Meier, T ; Meles, H. G ; Mengistu, G ; Miazgowski, T ; Mohamadnejad, M ; Mohammadian Hafshejani, A ; Mohammadoo Khorasani, M ; Mohammed, S ; Mohebi, F ; Mokdad, A. H ; Monasta, L ; Moossavi, M ; Moradzadeh, R ; Naik, G ; Negoi, I ; Nguyen, C. T ; Nguyen, L. H ; Nguyen, T. H ; Olagunju, A. T ; Olagunju, T. O ; Pennini, A ; Rabiee, M ; Rabiee, N ; Radfar, A ; Rahimi, M ; Rath, G.K ; Rawaf, D. L ; Rawaf, S ; Reiner, R. C ; Rezaei, N ; Rezapour, A ; Saad, A. M ; Saadatagah, S ; Sahebkar, A ; Salimzadeh, H ; Samy, A. M ; Sanabria, J ; Sarveazad, A ; Sawhney, M ; Sekerija, M ; Shabalkin, P ; Shaikh, M. A ; Sharma, R ; Sheikhbahaei, S ; Shirkoohi, R ; Siddappa Malleshappa, S. K ; Sisay, M ; Soreide, K ; Soshnikov, S ; Sotoudehmanesh, R ; Starodubov, V. I ; Subart, M. L ; Tabares Seisdedos, R ; Tadesse, D. B. B ; Traini, E ; Tran, B. X ; Tran, K. B ; Ullah, I ; Vacante, M ; Vahedian Azimi, A ; Varavikova, E ; Westerman, R ; Wondafrash, D. Z ; Xu, R ; Yonemoto, N ; Zadnik, V ; Zhang, Z. J ; Malekzadeh, R ; Naghavi, M ; GBD 2017 Pancreatic Cancer Collaborators ; Sharif University of Technology
Elsevier Ltd
2019
Abstract
Background: Worldwide, both the incidence and death rates of pancreatic cancer are increasing. Evaluation of pancreatic cancer burden and its global, regional, and national patterns is crucial to policy making and better resource allocation for controlling pancreatic cancer risk factors, developing early detection methods, and providing faster and more effective treatments. Methods: Vital registration, vital registration sample, and cancer registry data were used to generate mortality, incidence, and disability-adjusted life-years (DALYs) estimates. We used the comparative risk assessment framework to estimate the proportion of deaths attributable to risk factors for pancreatic cancer:...
Chemotherapeutic effects of Apigenin in breast cancer: Preclinical evidence and molecular mechanisms; enhanced bioavailability by nanoparticles
, Article Biotechnology Reports ; Volume 34 , 2022 ; 2215017X (ISSN) ; Zahmatkeshan, M ; Akbarzadeh, A ; Rabiee, N ; Ahmadi, S ; Keyhanvar, P ; Rezayat, S. M ; Seifalian, A. M ; Sharif University of Technology
Elsevier B.V
2022
Abstract
This review highlights using nanotechnology in increasing the bioavailability of AP (Apigenin) to enhance its therapeutic efficacy in breast cancer treatment. Breast cancer is one of the most leading causes of cancer death in women both in developed and developing countries. According to several epidemiological and clinical trial studies that indicate progestin-stimulated breast cancer in post-menopausal women; it is necessary to determine compounds to suppress or attenuate the tumor-promoting effects of progestins in breast cells. For this purpose, using the natural anti-progestins, including AP compared with the chemical ones could be significantly effective due to the lack of toxicities...